{"id":"placebo-to-match-jaktinib","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL6068498","moleculeType":"Vaccine component"},"_fixedAt":"2026-03-30T17:13:29.977793","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo-to-match formulations are inert preparations manufactured to be indistinguishable from the active drug in terms of appearance, taste, texture, and packaging. In this case, it mimics Jaktinib to maintain blinding in Phase 3 clinical trials, ensuring that neither patients nor some study personnel can identify whether they are receiving the active JAK inhibitor or placebo, thereby reducing bias in efficacy and safety assessments.","oneSentence":"This is a placebo formulation designed to match the appearance and administration of Jaktinib, a JAK inhibitor, for use as a control in clinical trials.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:43.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial)"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT05051761","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-09-04","conditions":"Alopecia Areata","enrollment":425},{"nctId":"NCT04617028","phase":"PHASE3","title":"Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-02-05","conditions":"Myelofibrosis","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match Jaktinib","genericName":"Placebo to match Jaktinib","companyName":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","companyId":"suzhou-zelgen-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation designed to match the appearance and administration of Jaktinib, a JAK inhibitor, for use as a control in clinical trials. Used for Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}